ArticleJournal of the Endocrine Society2026
Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Somapacitan, a long-acting GH derivative, has been used to treat adult GH deficiency. Although the distinct pharmacokinetics of somapacitan compared with daily GH administration are presumed to affect daily and weekly glucose profiles, detailed information on glucose fluctuations remains limited. Objective: Glycemic variability in individuals during somapacitan treatment was assessed. Methods: A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes. Participants receiving somatropin were switched to somapacitan, with doses titrated over 3 months to maintain IGF-1 levels within ± 2 SD. Continuous glucose monitoring was performed for 14 days before and after the switch. The primary endpoint was the change in glycemic variability indices. Results: With IGF-1 levels matched between regimens, no significant differences were observed in glycated hemoglobin A1c, fasting blood glucose, and insulin resistance index before and after switching to somapacitan. The continuous glucose monitoring data demonstrated that the mean sensor glucose level (SGL) and continuous overall net glycemic action over 24 hours were significantly increased during somapacitan treatment. Notably, whereas SGLs showed no significant interday fluctuations during somatropin treatment, biphasic glucose fluctuations were observed during somapacitan treatment, with mean SGLs peaking on the second day and reaching their lowest on the fourth day. After switching to somapacitan, the time below range tended to decrease across all days. Conclusion: The switch from somatropin to somapacitan resulted in increased interday glucose variability, characterized by biphasic glucose fluctuations, suggesting a unique physiological effect of somapacitan on glucose profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.